~~<i id='C04F38349C'><strike id='C04F38349C'><tt id='C04F38349C'><pre id='C04F38349C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

Wikipedia

author：focus 2025-10-01 23:05:51 - browse：2468

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： There’s a way to spot data fakery. All journals should be using it

entertainment

leisure time

focus

hotspot

entertainment

FormerPresidentDonaldTrumpspeakstocampaignvolunteersattheElksLodge,Tuesday,July18,2023,inCedarRapids

WSS

Microbiome research is starting to find links to chronic diseases

Microbiome research is starting to find links to chronic diseases

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Microbiome research is starting to find links to chronic diseases

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Second xenotransplant done with gene

leisure time

Wikipedia

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

Lasker Awards 2023: Winners in biomedical research

The high cost of giving birth even with insurance

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Supreme Court strikes down use of affirmative action

Hearing on Medicare drug price negotiation gets unusually heated

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Virtual Event: Putting AI to the Test

Hepatitis C has a cure — but many Americans still lack access to it

Sanders wants to replace patents with prizes for drug inventions

leisure time

FDA panel to weigh approval of NurOwn, controversial ALS drug

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Lasker Awards 2023: Winners in biomedical research

Thermo Fisher plant for manufacturing gene therapies to expand

In rare move, senator releases unverified FBI source report alleging Biden bribe

It's been 20 years since Dolly the sheep. Where's my clone?

leisure time

focus

hotspot

entertainment